The US Food and Drug Administration (FDA) has approved the marketing of DermaStream, the first product introduced by EnzySurge, an Israeli developer of solutions for the treatment of diabetic and pressure ulcers.
EnzySurge develops products for the treatment of chronic wounds that significantly reduce therapy time, accelerate healing and reduce care and hospital costs. DermaStream works through continuous, controlled irrigation of the patient's skin with therapeutic solutions. This therapeutic approach was developed by EnzySurge founder Prof. Amihay Freeman.
Following a successful series of animal testing, EnzySurge received the Helsinki Committee's permission to test the products on humans and is currently preparing for a clinical trial to be held at multiple medical centers across Israel. The trial will focus on diabetic and venous ulcers and is expected to serve as a major catalyst to the productױs market introduction.
MedicSense co-CEO Adi Ickowicz, who is also EnzySurge's manager of regulatory and quality affairs, said FDA approval for DermaStream covered a broad range of medical indications, facilitating the fast introduction of the product for additional clinical applications.
EnzySurge CEO Dr. Allon Leibovitz said, "The FDA approval will allow us to expand our business presence in the US. Half the patients suffering from hard-to-heal wounds, including diabetic and pressure sores, are located in the USA, meaning a potential market of 5 million people. FDA clearance opens the door to marketing and business development opportunities in the US. We are also considering several possible partnerships, some of them with American companies. The FDA approval will play a major role in leveraging these opportunities."
To date, EnzySurge has raised close to $2 million from private investors through Eli Gilboa CPA, of the Gilboa & Licht Investment House. Gilboa also serves as chairman of EnzySurge's board of directors. The company has received funding from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade.
EnzySurge was founded in 2001 by Ramot at Tel Aviv University, Ltd. and Prof. Freeman, director of the Institute of Biotechnology of Tel-Aviv University and an expert in the field of enzymatic processes.
Published by Globes [online], Israel business news - www.globes.co.il - on March 22, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006